04.30.26 -- Mapping Candel Therapeutics' Sprint To The BLA Finish Line

Embrace the future of drug development by leveraging AI and innovative protein synthesis technologies to accelerate the creation of effective therapies and transform patient outcomes.

Navigate the challenging path from concept to clinical reality by partnering with an experienced CDMO that can provide the regulatory, clinical, and CMC expertise needed to move your therapeutic forward.

Using cells with a pre-engineered landing pad, we achieve inducible expression within just 4-6 weeks after donor plasmid creation, significantly reducing development time and effort.

Conducted alongside the Faculty of Medicine at Palacky University and supported by the Technology Agency of the Czech Republic, this project focused on translating research into a viable product.

Discover how a people-first talent strategy, purpose-driven culture, and cross-functional collaboration come together to support scalable growth and operational excellence in commercial manufacturing.

Common GMP pitfalls stem from poor scalability, late regulatory planning, weak tech transfer, unsuitable hosts, and inadequate quality systems, delaying biologics production timelines and budgets.

Operational excellence in drug manufacturing comes from predictability. Standardized, consistent processes reduce volatility and ensure steady, high‑quality progress.

Bridge the gap between in vitro research and human physiology by utilizing high-purity primary cells. Accessing diverse cell types ensures your gene therapy discovery remains biologically relevant.

See how one family managed to get an investigational gene replacement therapy manufactured and approved by the FDA so their daughter could be dosed just 14 months from her diagnosis.

Animal‑free soy‑based materials provide consistent molecular weight profiles, stable mineral levels, and controlled manufacturing to ensure reliable, reproducible bioprocessing performance.